Macular Pigment Optical Density as a Measurable Modifiable Clinical Biomarker
Nutrients · 27.09.2024 · 16 (19) · 3273
DOI: 10.3390/nu16193273 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nutrients, online erschienen am 27.09.2024. Verfasst von Abdul Masri und 5 weiteren Autor:innen. Beteiligte Einrichtung: Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA. Hauptthemen laut MEDLINE: Macular Pigment, Biomarkers, Macular Degeneration. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Carotenoids are present throughout retina and body its dense deposition leads to an identifiable yellow spot in the macula. Macular pigment optical density (MPOD) measured in the macula is vital to macular well-being and high-resolution visual acuity. MPOD has also been associated with various health and disease states. We sought to review the literature on this topic and summarize MPODs role as a measurable modifiable clinical biomarker, particularly as a measure of the eye’s antioxidant capacity in the context of oxidative damage and retinal ischemia.
Methods
A literature review collated the articles relevant to MPOD, carotenoid intake or supplementation, and their influence on various health and disease states.
Results
Literature reveals that MPOD can serve as a reliable biomarker for assessing the retinal defense mechanisms against oxidative stress and the deleterious effects of excessive light exposure. Elevated MPOD levels offer robust protection against the onset and progression of age-related macular degeneration (AMD), a prevalent cause of vision impairment among the elderly population. MPOD’s implications in diverse ocular conditions, including diabetic retinopathy and glaucoma, have been explored, underscoring the real need for clinical measurement of MPOD. The integration of MPOD measurement into routine eye examinations presents an unparalleled opportunity for early disease detection, precise treatment planning, and longitudinal disease monitoring.
Conclusions
Longitudinal investigations underscore the significance of MPOD in the context of age-related ocular diseases. These studies show promise and elucidate the dynamic nuances of MPOD’s status and importance as a measurable, modifiable clinical biomarker.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Arizona College of Osteopathic Medicine, Midwestern University, Glendale, AZ 85308, USA.
- College of Medicine, University of Saskatchewan, Saskatoon, SK S7N 5A2, Canada.
- College of Optometry, Western University of Health Sciences, Pomona, CA 91766, USA.
- EyePromise, LLC, Chesterfield, MO 63005, USA.
- Arizona College of Optometry, Midwestern University, Glendale, AZ 85308, USA.
ORCID-Profile: Keiko Inouye, Pinakin Gunvant Davey, Balamurali Vasudevan
Zitieren
APA
Masri, A., Armanazi, M., Inouye, K., Geierhart, D. L., Davey, P. G., & Vasudevan, B. (2024). Macular Pigment Optical Density as a Measurable Modifiable Clinical Biomarker. Nutrients, 16(19), 3273. https://doi.org/10.3390/nu16193273
Vancouver
Masri A, Armanazi M, Inouye K, Geierhart DL, Davey PG, Vasudevan B. Macular Pigment Optical Density as a Measurable Modifiable Clinical Biomarker. Nutrients. 2024;16(19):3273. doi:10.3390/nu16193273
BibTeX
@article{Masri2024,
author = {Masri, Abdul and Armanazi, Mohammed and Inouye, Keiko and Geierhart, Dennis L and Davey, Pinakin Gunvant and Vasudevan, Balamurali},
title = {Macular Pigment Optical Density as a Measurable Modifiable Clinical Biomarker},
journal = {Nutrients},
year = {2024},
volume = {16},
number = {19},
pages = {3273},
doi = {10.3390/nu16193273}
}
EUVIMED